Rethink your Impurity Analysis Strategy
In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Experts provide an overview of ex vivo and in vitro methods, techniques, and model systems for research within the cancer-immunity cycle framework.
Biomarker Imaging for Preclinical Cancer Research
Cancer biomarkers that do not cross the translational gap to clinical practice can still further research and drug discovery. In this article, we review several techniques commonly used for cancer biomarker imaging at preclinical stages, as well as recent technological advances.
Are In Vitro Metabolism and Drug-Drug Interaction Studies Critical for an Investigational New Drug Application?
Andrew G. Taylor, PhD provides an overview of processes by which drugs are metabolized and discusses the importance of drug metabolism and drug-drug interaction studies.
Overcoming Critical Issues in Glioblastoma Multiforme (GBM) Therapeutic Development
This article, originally published on Scientist.com, reviews the current standard of care for glioblastoma multiforme (GBM), challenges in developing accurate preclinical GBM models and effective therapies, and the future of GBM drug discovery.
Intestinal Toxicity Assessment with Patient-Derived Organoids
Dr. Martin Stahl describes the use of patient-derived intestinal organoids to assess the toxicity of potential therapeutic compounds and study barrier function in a human-specific model system.
Discovering a Novel Therapy for Urinary Tract Infections
Originally published on Scientist.com, this article provides an overview of antimicrobial therapies, antimicrobial resistance, and advantages of in silico methods for drug discovery.
Cell Painting: The Colorful Future of Drug Discovery
A panel Q&A originally published on Scientist.com that introduces cell painting and highlights its value in preclinical and early drug discovery programs.
Recent Advances in Anti-Obesity Pharmacological Research
A review of current obesity treatments and their limitations, the need for animal models in obesity research, and emerging anti-obesity medications including incretin-based therapies, mitochondrial uncouplers, and various phytochemicals.
Optimize the Value of Your Research Investment: Outsourcing Molecule Design
Dr. Martin Slater discusses common challenges in molecule design and how they can be overcome with computational chemistry methods.
Current and Novel Immuno-Oncology Drug Evaluation Methods via Humanized Mouse Models
Dr. Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Cutting Edge Conversations: Discovering New Innovations in Oncology
Experts discuss progress in cancer research, including novel treatments, experimental therapies, and drug development.
Cutting Edge Conversations: Challenges in Sourcing Human Biosamples
Richard Kondo, McLean Collins, and Cathie G. Miller highlighted Episode 3 of the Cutting Edge Conversations series focused on innovations in the area of sourcing human biosamples for research. The event focused on sourcing human samples for research, including the value and necessity of working with human tissue during drug discovery, as well as some of the distinct challenges researchers face.
Translational Applications of MiniPDX: An In Vivo Organoid Assay in New Drug R&D
Join Dr. Danyi Wen as she describes a novel drug efficacy test using Patient Derived Xenograft (PDX) samples to measure drug efficacy and identify therapeutic candidates in personalized oncology treatments.
Using Chemical Denaturants and Light Scattering to Determine Aggregation Propensity of Biopharmaceuticals
Dr. Luke Holloway reviews light scattering-based methods for protein characterization and explains their utility, when combined with partially denaturing buffers, in understanding aggregation propensity of monoclonal antibodies.
Plasma Proteomics: The Next Frontier of Biomarker Discovery in the Precision Medicine Era
Plasma proteomics is increasingly recognized as a fundamental approach to accelerate biomarker discovery and drug development, taking precision medicine to the next level.
Detection of Protein Aggregation During Biopharmaceutical Development: The Role of Orthogonal Techniques
Dr. Danny Chou discusses the opportunities and challenges in orthogonal particle analysis, and how flow imaging microscopy and light obscuration can be used for formulation development and quality control.
Casting a Wider Net in Zebrafish Screening with Automated Microscopy and Image Analysis
Join Dr. Alexandra Lubin and Dr. Jason Otterstrom as they discuss the use of deep learning-powered automated microscopy and image analysis for fast, in vivo zebrafish screening.
